Breast Cancer Now media statements
We respond to NHS England breast cancer waiting times: January 2022
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
Breast Cancer Now responds to latest NHSE Cancer Wait Times data, calling for the FDS to be raised to 95%
Baroness Delyth Morgan, Chief Executive of Breast Cancer Now, responded to the latest NHS England cancer waiting times data, calling for the...
Fantastic outcome for certain patients with incurable secondary triple negative breast cancer as pembrolizumab (Keytruda) in combination with chemo (paclitaxel or nab-paclitaxel) is approved for use on the NHS in Scotland
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said that the approval of pembrolizumab (Keytruda) in combination with chemo f...
We welcome approval of palbociclib with fulvestrant for routine use on the NHS
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said the approval of palbociclib with fulvestrant for routine use on the NHS w...
We respond to the news that NICE has rejected Inavolisib with palbociclib and fulvestrant for use on the NHS in England
Claire Rowney, chief executive at Breast Cancer Now, said: